Blog

A pharmaceutical company's attempt to win approval for a new Alzheimer's treatment, simufilam, continues amid a flurry of controversy and regulatory challenges. Recent investigations have cast doubt on the basic studies supporting simufilam. These concerns increased when scientific journals retracted several studies and key figures at Cassava Sciences, the drug's sponsor, resigned. Despite these setbacks, in September the Securities and Exchange Commission (SEC) accused Cassava Sciences of disseminating misleading data about their clinical trials. However, the company settled these charges by paying $40 million, without admitting any guilt. Interestingly, simufilam is still undergoing Phase 3 trials, involving more than 1,900…

In the unexpected event of the owner's death, the fate of his beloved pets often becomes uncertain. This concern prompted Tracy Jennings, a landscaper in Buffalo, Minnesota, to take proactive steps to ensure her pets were well cared for in her absence. After witnessing the distressing outcome of her friend's animals who were hastily rehomed and subsequently euthanized, Jennings decided to set up a legally binding animal trust. A pet trust fund is not simply a thoughtful gesture; This is a solid agreement that designates a caretaker for pets and allocates funds to manage their expenses, such as veterinary care,…